The global dysmenorrhea treatment market is anticipated to grow at a considerable CAGR of 8.1% during the forecast period (2022-2028). Dysmenorrhea is a common gynaecological condition that affects women of all ages and races. It is one of the most commonly diagnosed causes of pelvic pain in women. The symptoms associated with dysmenorrhea include gastrointestinal symptoms such as diarrhoea, nausea, bloating, constipation, or both, along with vomiting and indigestion. According to the National Centre for Biotechnology Information the prevalence of dysmenorrhea can vary between 16% and 91% in women of reproductive age, with severe pain observed in 2% to 29%. Dysmenorrhea is associated with significant impairment in quality of life between 16% to 29% of women. Furthermore, 12% of the monthly school and work activities are lost due to absenteeism because of dysmenorrhea.
Browse the full report description of “Global Dysmenorrhea Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormonal Therapy), By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea) Forecast Period 2022-2028” at https://www.omrglobal.com/industry-reports/dysmenorrhea-treatment-market
Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in May 2020, Mochida Pharmaceutical Co., Ltd announced the launch of DINAGEST Tablets 0.5 mg a therapeutic agent for dysmenorrhea. DINAGEST Tablets 1 mg, a therapeutic agent for endometriosis, was licensed from Jenapharm, a subsidiary of Bayer AG, and developed by Mochida. The drug is marketed in Japan since 2008 and an additional indication, reduction of pain caused by adenomyosis.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Treatment Type
o By Type
• Regions Covered
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Dysmenorrhea Treatment Market Report by Segment
By Treatment Type.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Hormonal Therapy
By Type
• Primary Dysmenorrhea
• Secondary Dysmenorrhea
Global Dysmenorrhea Treatment Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/dysmenorrhea-treatment-market